CA2497960A1 - Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene - Google Patents
Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene Download PDFInfo
- Publication number
- CA2497960A1 CA2497960A1 CA002497960A CA2497960A CA2497960A1 CA 2497960 A1 CA2497960 A1 CA 2497960A1 CA 002497960 A CA002497960 A CA 002497960A CA 2497960 A CA2497960 A CA 2497960A CA 2497960 A1 CA2497960 A1 CA 2497960A1
- Authority
- CA
- Canada
- Prior art keywords
- epo
- erythropoietin
- linked oligosaccharide
- tissue protective
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40902002P | 2002-09-09 | 2002-09-09 | |
US60/409,020 | 2002-09-09 | ||
PCT/US2003/028073 WO2004022577A2 (fr) | 2002-09-09 | 2003-09-09 | Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2497960A1 true CA2497960A1 (fr) | 2004-03-18 |
Family
ID=31978712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002497960A Withdrawn CA2497960A1 (fr) | 2002-09-09 | 2003-09-09 | Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1545586A4 (fr) |
JP (1) | JP2006511468A (fr) |
KR (1) | KR20050083682A (fr) |
CN (2) | CN1729015A (fr) |
AU (1) | AU2003273297A1 (fr) |
BR (1) | BR0314152A (fr) |
CA (1) | CA2497960A1 (fr) |
EA (1) | EA007812B1 (fr) |
IL (1) | IL174178A0 (fr) |
IS (1) | IS7731A (fr) |
MX (1) | MXPA05002617A (fr) |
NO (1) | NO20051714L (fr) |
PL (1) | PL375741A1 (fr) |
WO (1) | WO2004022577A2 (fr) |
ZA (1) | ZA200505423B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
WO2006061853A2 (fr) * | 2004-12-10 | 2006-06-15 | Serum Institute Of India Limited | Nouveaux composes erythropoietiques et leur procede de production |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
KR20170027868A (ko) | 2005-08-05 | 2017-03-10 | 아라임 파마슈티칼즈, 인크. | 조직 보호 펩티드 및 이의 용도 |
NZ587105A (en) | 2008-01-22 | 2012-09-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
CN101671388B (zh) * | 2008-09-09 | 2013-01-02 | 曹国栋 | 血脑屏障穿透性促红细胞生成素及其应用 |
RU2475273C1 (ru) * | 2012-04-02 | 2013-02-20 | Юлия Николаевна Козлова | Способ получения полимерного цемента медицинского назначения |
CN102746405B (zh) * | 2012-07-24 | 2013-08-21 | 深圳赛保尔生物药业有限公司 | 重组人促红素的连续聚乙二醇化反应方法 |
RU2664588C2 (ru) * | 2015-11-05 | 2018-08-21 | Закрытое Акционерное Общество "Биокад" | Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе |
US10864253B2 (en) | 2016-04-29 | 2020-12-15 | Araim Pharmaceuticals, Inc. | Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage |
CN112741895A (zh) * | 2021-01-19 | 2021-05-04 | 中国人民解放军陆军军医大学 | Epo类似物在制备治疗脓毒症药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
ES2306711T3 (es) * | 2000-04-21 | 2008-11-16 | Amgen Inc. | Metodo y composicion destinada a la prevencion y al tratamiento de la anemia. |
ATE291436T2 (de) * | 2000-05-15 | 2005-04-15 | Hoffmann La Roche | Flüssige arzneizubereitung enthaltend ein erythropoietin derivat |
-
2003
- 2003-09-09 EP EP03755796A patent/EP1545586A4/fr not_active Withdrawn
- 2003-09-09 WO PCT/US2003/028073 patent/WO2004022577A2/fr active Application Filing
- 2003-09-09 CA CA002497960A patent/CA2497960A1/fr not_active Withdrawn
- 2003-09-09 MX MXPA05002617A patent/MXPA05002617A/es unknown
- 2003-09-09 ZA ZA200505423A patent/ZA200505423B/xx unknown
- 2003-09-09 PL PL03375741A patent/PL375741A1/xx not_active Application Discontinuation
- 2003-09-09 BR BR0314152-7A patent/BR0314152A/pt not_active IP Right Cessation
- 2003-09-09 AU AU2003273297A patent/AU2003273297A1/en not_active Abandoned
- 2003-09-09 CN CNA038249154A patent/CN1729015A/zh active Pending
- 2003-09-09 JP JP2004534745A patent/JP2006511468A/ja not_active Withdrawn
- 2003-09-09 CN CNA2008101490873A patent/CN101371920A/zh active Pending
- 2003-09-09 EA EA200500473A patent/EA007812B1/ru not_active IP Right Cessation
- 2003-09-09 KR KR1020057004045A patent/KR20050083682A/ko not_active Application Discontinuation
-
2005
- 2005-03-08 IS IS7731A patent/IS7731A/is unknown
- 2005-04-06 NO NO20051714A patent/NO20051714L/no not_active Application Discontinuation
-
2006
- 2006-03-08 IL IL174178A patent/IL174178A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IS7731A (is) | 2005-03-08 |
KR20050083682A (ko) | 2005-08-26 |
ZA200505423B (en) | 2008-08-27 |
EA007812B1 (ru) | 2007-02-27 |
JP2006511468A (ja) | 2006-04-06 |
WO2004022577A3 (fr) | 2004-09-16 |
EP1545586A4 (fr) | 2007-09-26 |
WO2004022577A2 (fr) | 2004-03-18 |
CN1729015A (zh) | 2006-02-01 |
IL174178A0 (en) | 2006-08-01 |
EP1545586A2 (fr) | 2005-06-29 |
AU2003273297A1 (en) | 2004-03-29 |
BR0314152A (pt) | 2005-07-12 |
CN101371920A (zh) | 2009-02-25 |
MXPA05002617A (es) | 2005-09-08 |
EA200500473A1 (ru) | 2005-10-27 |
AU2003273297A8 (en) | 2004-03-29 |
PL375741A1 (en) | 2005-12-12 |
NO20051714L (no) | 2005-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050176627A1 (en) | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin | |
WO2005025606A1 (fr) | Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene | |
JP6491621B2 (ja) | 組織保護ペプチド及びその使用 | |
KR100985615B1 (ko) | 에리트로포이에틴-응답 세포, 조직 및 기관의 보호, 회복 및 향상 | |
US7767643B2 (en) | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs | |
ES2539759T3 (es) | Proteínas de fusion humanas recombinantes de EPO-Fc con vida media prolongada y actividad eritropoyética in vivo mejorada | |
US20040209802A1 (en) | Treatment of disturbances of iron distribution | |
AU2002239665A1 (en) | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs | |
CZ299516B6 (cs) | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem | |
JP4153036B2 (ja) | 截形グリア細胞系由来神経栄養因子 | |
PT866719E (pt) | Metodo de tratamento de lesao de celulas do ganglio retinal utilizando o produto proteico factor neurotrofico derivado da linha de celulas da glia (gdnf) | |
PT863766E (pt) | Metodos de tratamento de lesao ou degeneracao de fotorreceptores utilizando o produto proteico factor neurotrofico derivado da linha de celulas da glia (gdnf) | |
CA2497960A1 (fr) | Erythropoietines a action longue qui maintiennent l'activite protectrice du tissu d'une erythropoietine endogene | |
US20040209812A1 (en) | Use of erythropoietin in stroke recovery | |
US20040077543A1 (en) | Treatment using neublastin polypeptides | |
JP2009510008A (ja) | 神経変性障害の処置 | |
AU2004260543A8 (en) | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin | |
KR20060132803A (ko) | 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는장기 작용성 에리트로포이에틴 | |
JP2001524944A (ja) | 神経障害性疼痛の緩和方法 | |
ZA200508695B (en) | Use of erythropoietin in stroke recovery | |
AU2007200697A1 (en) | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
AZWI | Withdrawn application |